Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
nebulizer
Pharma
Mannkind wraps up phase 1 trial of inhaled lung infection asset
MannKind has wrapped up a phase 1 clinical trial of an inhaled formulation of clofazimine, teeing it up to talk to the FDA about advancing the asset.
Nick Paul Taylor
Sep 6, 2022 9:35am
Celltrion races inhaled COVID-19 antibody therapy into phase 3
Feb 7, 2022 7:30am
Omicron spurs Celltrion to speed development of nebulized drug
Nov 30, 2021 9:25am
Verona sells Chinese rights to inhaled drug for $40M upfront
Jun 14, 2021 8:15am
Avalyn advances inhaled twist on Roche fibrosis drug
May 25, 2021 7:50am
CSL taps HCmed to deliver immunoglobulins to the lungs
May 4, 2021 7:45am
